Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report)'s stock price traded up 6.2% during mid-day trading on Thursday . The stock traded as high as $16.80 and last traded at $17.06. 33,726 shares traded hands during trading, a decline of 87% from the average session volume of 259,109 shares. The stock had previously closed at $16.07.
Analysts Set New Price Targets
ELVN has been the topic of several research analyst reports. HC Wainwright upped their price target on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday, May 15th. Jones Trading decreased their target price on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $37.25.
Read Our Latest Analysis on ELVN
Enliven Therapeutics Stock Performance
The stock has a market capitalization of $875.39 million, a P/E ratio of -9.39 and a beta of 1.07. The business's fifty day moving average price is $18.01 and its two-hundred day moving average price is $20.96.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.06). As a group, analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.
Insider Activity at Enliven Therapeutics
In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 5,000 shares of the business's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $16.07, for a total transaction of $80,350.00. Following the completion of the transaction, the insider now owns 997,688 shares in the company, valued at $16,032,846.16. The trade was a 0.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Samuel Kintz sold 12,500 shares of the company's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $20.83, for a total transaction of $260,375.00. Following the completion of the transaction, the chief executive officer now owns 990,392 shares of the company's stock, valued at approximately $20,629,865.36. The trade was a 1.25% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 86,111 shares of company stock worth $1,643,398. 29.20% of the stock is owned by company insiders.
Institutional Trading of Enliven Therapeutics
A number of large investors have recently bought and sold shares of the business. SG Americas Securities LLC increased its holdings in Enliven Therapeutics by 66.1% during the 4th quarter. SG Americas Securities LLC now owns 16,629 shares of the company's stock valued at $374,000 after acquiring an additional 6,616 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Enliven Therapeutics by 14.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company's stock valued at $233,000 after purchasing an additional 1,275 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Enliven Therapeutics by 2.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 261,888 shares of the company's stock valued at $5,892,000 after purchasing an additional 6,611 shares during the period. Swiss National Bank increased its stake in shares of Enliven Therapeutics by 13.9% in the fourth quarter. Swiss National Bank now owns 41,873 shares of the company's stock worth $942,000 after buying an additional 5,100 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in Enliven Therapeutics in the fourth quarter worth $367,000. Institutional investors and hedge funds own 95.08% of the company's stock.
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Articles
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
